![January/February 2023: A 24-week, All-Oral Regimen for Rifampin-Resistant Tuberculosis](https://icap.columbia.edu/wp-content/uploads/resource-image-fix.jpg)
Journal Club
![January/February 2023: A 24-week, All-Oral Regimen for Rifampin-Resistant Tuberculosis](https://icap.columbia.edu/wp-content/uploads/resource-image-fix.jpg)
![Nov/Dec 2022: Fee for home delivery and monitoring of antiretroviral therapy for HIV infection compared with standard clinic-based services in South Africa: A randomised controlled trial](https://icap.columbia.edu/wp-content/uploads/Untitled-design-68-1080x675.png)
Nov/Dec 2022: Fee for home delivery and monitoring of antiretroviral therapy for HIV infection compared with standard clinic-based services in South Africa: A randomised controlled trial
Article and Study Summary: Fee for home delivery and monitoring of antiretroviral therapy for HIV infection compared with standard clinic-based services in South Africa: A randomised controlled trial Published in: Lancet HIV. 2022....![October 2022: Comparing dedicated and designated approaches to integrating task-shared psychological interventions into chronic disease care in South Africa: a three-arm, cluster randomised, multicentre, open-label trial](https://icap.columbia.edu/wp-content/uploads/Untitled-design-58-1080x675.png)
October 2022: Comparing dedicated and designated approaches to integrating task-shared psychological interventions into chronic disease care in South Africa: a three-arm, cluster randomised, multicentre, open-label trial
Article and Study Summary: Comparing dedicated and designated approaches to integrating task-shared psychological interventions into chronic disease care in South Africa: a three-arm, cluster randomised, multicentre, open-label trial Published in: Lancet. 2022; 400...![September 2022: Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis](https://icap.columbia.edu/wp-content/uploads/Untitled-design-43-1080x675.png)
September 2022: Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis
Article and Study Summary: Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis Published in: N Engl J Med. 2022;387(9):810-823 Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis Authors: Conradie F, Bagdasaryan TR, Borisov...![July 2022: Efficiency of 6-month PrEP dispensing with HIV self-testing in Kenya](https://icap.columbia.edu/wp-content/uploads/Untitled-design-16-1080x675.png)